Eli Lilly and price to sales ratio LLY

Market value divided by revenue over the last twelve months, since 2009.

Today, Oct 23, 2026: 15.0×
10-year median: 8.8×
Against its 10-year history: 76th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.6× to 25.1×
Peer median: 6.2×

Eli Lilly and's price to sales ratio is 15.0× as of Oct 23, 2026.

That is above its ten-year median of 8.8×, higher than on 76% of days in the last ten years.

Over that time it ranged from 3.6× in Mar 2018 to 25.1× in Jul 2024.

The median for 7 large drugmakers of a similar size is 6.2×.

Price to sales ratio over time

median 8.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.0×	12.4×	17.2×
2025	17.1×	11.1×	19.4×
2024	18.2×	17.3×	25.1×
2023	17.3×	10.5×	19.6×
2022	11.9×	8.1×	12.2×
2021	9.5×	6.9×	9.7×
2020	7.0×	5.2×	7.1×
2019	5.6×	4.3×	5.6×
2018	5.0×	3.6×	5.2×
2017	4.1×	3.9×	4.5×
2016	3.9×	3.6×	4.6×
2015	4.7×	3.8×	5.0×
2014	3.9×	2.5×	4.0×
2013	2.5×	2.4×	2.9×
2012	2.5×	1.9×	2.6×
2011	2.0×	1.7×	2.0×
2010	1.8×	1.7×	1.9×
2009	1.9×	1.8×	2.0×

Against its peers

Companies in Drug Manufacturers - General nearest Eli Lilly and's size, closest first, today.

Company	Price to sales ratio
LLYEli Lilly and	15.0×
JNJJohnson & Johnson	6.4×
ABBVAbbVie	7.8×
MRKMerck	5.4×
AMGNAmgen	6.2×
GILDGilead Sciences	6.4×
PFEPfizer	2.7×
BMYBristol-Myers Squibb	2.6×
Peer median	6.2×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Eli Lilly and

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.